The fight against the Corona pandemic is a global one. It will take an indeterminate amount of time before sufficient vaccine is produced, distributed and administered worldwide. Time that will allow the virus to form new mutations and resistances. Currently, there are no approved drugs against the disease that are sufficiently effective and address the virus as well as the highly variable disease progression and symptoms. Innovative biotechnology companies around the world are therefore searching for effective drugs to mitigate the course of COVID-19 disease.
Our keynote speaker Rob Schott, Senior Vice President and Chief Development Officer at Sangamo Therapeutics, will provide an overview of the global approaches to COVID-19 therapy development. Afterwards we will be taking a look at the range of German projects in this area.
The keynote will take place on April 30 between 10:30 and 10:50 am, the following program focus introduces six German companies active in this area and a panel discussion on COVID-19 therapies.